MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1073/pnas.2106433118

Медицинская библиотека · Proceedings of the National Academy of Sciences of the United States of America · 2021

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.

King Hannah A D, Joyce M Gordon, Lakhal-Naouar Ines, Ahmed Aslaa, Cincotta Camila Macedo, Subra Caroline, Peachman Kristina K, Hack Holly R, Chen Rita E, Thomas Paul V, Chen Wei-Hung, Sankhala Rajeshwer S, Hajduczki Agnes, Martinez Elizabeth J, Peterson Caroline E, Chang William C, Choe Misook, Smith Clayton, Headley Jarrett A, Elyard Hanne A, Cook Anthony, Anderson Alexander, Wuertz Kathryn McGuckin, Dong Ming, Swafford Isabella, Case James B, Currier Jeffrey R, Lal Kerri G, Amare Mihret F, Dussupt Vincent, Molnar Sebastian, Daye Sharon P, Zeng Xiankun, Barkei Erica K, Alfson Kendra, Staples Hilary M, Carrion Ricardo, Krebs Shelly J, Paquin-Proulx Dominic, Karasavvas Nicos, Polonis Victoria R, Jagodzinski Linda L, Vasan Sandhya, Scott Paul T, Huang Yaoxing, Nair Manoj S, Ho David D, de Val Natalia, Diamond Michael S, Lewis Mark G, Rao Mangala, Matyas Gary R, Gromowski Gregory D, Peel Sheila A, Michael Nelson L, Modjarrad Kayvon, Bolton Diane L

СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАПеревод в очереди

Аннотация

Emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the need for next-generation vaccines able to elicit broad and durable immunity. Here we report the evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ). RFN vaccination of macaques using a two-dose regimen resulted in robust, predominantly Th1 CD4+ T cell responses and reciprocal peak mean serum neutralizing antibody titers of 14,000 to 21,000. Rapid control of viral replication was achieved in the upper and lower airways of animals after high-dose SARS-CoV-2 respiratory challenge, with undetectable replication within 4 d in seven of eight animals receiving 50 µg of RFN. Cross-neutralization activity against SARS-CoV-2 variant B.1.351 decreased only approximately twofold relative to WA1/2020. In addition, neutralizing, effector antibody and cellular responses targeted the heterotypic SARS-CoV-1, highlighting the broad immunogenicity of RFN-ALFQ for SARS-CoV-like Sarbecovirus vaccine development.

Для цитирования: King Hannah A D, Joyce M Gordon, Lakhal-Naouar Ines, Ahmed Aslaa, Cincotta Camila Macedo, Subra Caroline, Peachman Kristina K, Hack Holly R, Chen Rita E, Thomas Paul V, Chen Wei-Hung, Sankhala Rajeshwer S, Hajduczki Agnes, Martinez Elizabeth J, Peterson Caroline E, Chang William C, Choe Misook, Smith Clayton, Headley Jarrett A, Elyard Hanne A, Cook Anthony, Anderson Alexander, Wuertz Kathryn McGuckin, Dong Ming, Swafford Isabella, Case James B, Currier Jeffrey R, Lal Kerri G, Amare Mihret F, Dussupt Vincent, Molnar Sebastian, Daye Sharon P, Zeng Xiankun, Barkei Erica K, Alfson Kendra, Staples Hilary M, Carrion Ricardo, Krebs Shelly J, Paquin-Proulx Dominic, Karasavvas Nicos, Polonis Victoria R, Jagodzinski Linda L, Vasan Sandhya, Scott Paul T, Huang Yaoxing, Nair Manoj S, Ho David D, de Val Natalia, Diamond Michael S, Lewis Mark G, Rao Mangala, Matyas Gary R, Gromowski Gregory D, Peel Sheila A, Michael Nelson L, Modjarrad Kayvon, Bolton Diane L. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.. Proceedings of the National Academy of Sciences of the United States of America. 2021. DOI: 10.1073/pnas.2106433118.

Предметные рубрики MeSH

Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesFerritinsMacaca mulattaNanoparticlesReceptors, VirusSARS-CoV-2T-Lymphocytes
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.